ACADIA Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

CEO

Catherine Owen Adams

CEOCatherine Owen Adams

Employees

654

Employees654

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1993

Founded1993

Employees

654

Employees654

ACAD Key Statistics

Market cap

3.57B

Market cap3.57B

Price-Earnings ratio

15.73

Price-Earnings ratio15.73

Dividend yield

—

Dividend yield—

Average volume

2.34M

Average volume2.34M

High today

$21.34

High today$21.34

Low today

$20.81

Low today$20.81

Open price

$21.14

Open price$21.14

Volume

624.43K

Volume624.43K

52 Week high

$26.65

52 Week high$26.65

52 Week low

$13.40

52 Week low$13.40

ACAD News

Simply Wall St 4h

ACADIA Pharmaceuticals: Assessing Valuation After Phase 3 Carbetocin Setback and New Legal Scrutiny

ACADIA Pharmaceuticals (ACAD) saw its stock react after disclosing that its Phase 3 COMPASS PWS study for intranasal carbetocin missed both primary and secondar...

TipRanks 6h

Acadia Pharmaceuticals initiated with a Buy at Citi

Citi initiated coverage of Acadia Pharmaceuticals (ACAD) with a Buy rating and $33 price target The firm believes Nuplazid and Daybue adoption will continue to...

TipRanks 1d

ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product Focus

ACADIA Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sean Laaman from Morgan Stanley maintained a Ho...

Analyst ratings

63%

of 19 ratings

Buy

63.2%

Hold

31.6%

Sell

5.3%

More ACAD News

Simply Wall St 6d

Do ACADIA Pharmaceuticals’ Pipeline Updates Reveal a Shifting Focus Beyond NUPLAZID?

Acadia Pharmaceuticals recently presented a late-breaker oral platform presentation and two poster sessions at the International Congress of Parkinson's Disease...

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.